Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

Medically Reviewed by: OneDayMD Editorial Team
Last Updated: May 2026

Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X.

This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels).

Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions.

Who is Dr. William Makis

Dr. William Makis is a Canadian-trained physician and former oncologist (McGill Medicine, 110+ peer-reviewed publications) who currently practices in Florida, USA. He maintains a highly active Substack publication documenting cancer remission and reversal cases, alongside his clinical experiences treating cancer patients using metabolic-based approaches combined with fenbendazole, ivermectin, and mebendazole — in some cases alongside conventional chemotherapy.

He also shares information publicly through X, including anonymized patient updates, treatment progress reports, and dosing regimen discussions. (stereomatch.substack.com)

Why This Protocol Matters in 2026

Dr. Makis has treated a large volume of cancer patients using repurposed drugs since 2023. His approach centres on high-dose ivermectin combined with benzimidazoles (fenbendazole and/or mebendazole) alongside synergistic supplements and metabolic interventions. He customizes per patient, but the core protocol patterns have become increasingly consistent.

This continuously updated 2026 guide compiles Dr. Makis’s latest protocols from his Substack, X posts, and patient correspondence — cross-referencing dosages, schedules, combinations, safety data, sourcing, and real patient outcomes.

Dr. Makis's Core Ivermectin Cancer Protocols 2025 - 2026

1. Standard Protocol – Most common cancers

• Applicable cancers: Breast, Colon, Lung, Prostate, Melanoma, Renal, Gastric
• Ivermectin dosage: 1.0 mg/kg/day (example: 80 kg patient = 80 mg/day) – taken daily, no days off
• Benzimidazole partner: Fenbendazole 444–1000 mg/day OR Mebendazole 1000 mg/day
• Key add-ons: Berberine 500 mg 2–3×/day, CBD oil 100 mg/day
• Duration: Minimum 3–6 months or until NED (No Evidence of Disease)

Evidence level: Anecdotal case reports + observational cohort (Hulscher et al., 2026)

2. Aggressive / Turbo Cancer Protocol

• Applicable cancers: Lymphoma, Leukemia, Pancreatic, GBM, Sarcoma, Triple-Negative Breast, Turbo cancers*.

*Turbo cancers” is a colloquial term for aggressive, rapid-onset cancers — not a formal oncological classification.

• Ivermectin dosage: 1.5–2.0 mg/kg/day (many patients are now on 2 mg/kg or higher under monitoring)
• Benzimidazole partner: Fenbendazole 1000 mg/day + Mebendazole 1000–1500 mg/day (dual or triple therapy)
• Key add-ons: Methylene Blue 50–100 mg/day, high-dose Berberine, DMSO topical on tumors
• Duration: Daily until major response, then taper only after NED confirmed.

Evidence level: Anecdotal case reports

3. Low-Dose Ivermectin + High-Dose Benzimidazole Protocol

• Applicable cancers: Ovarian, Uterine, some Breast cancers (when patient cannot tolerate high ivermectin)
• Ivermectin dosage: 0.5–1.0 mg/kg/day
• Benzimidazole partner: Fenbendazole 1000–2222 mg/day (continuous or 3 days on/4 off)
• Key add-ons: CBD/THC oils, Berberine, Curcumin liposomal
• Duration: 6–12 months minimum

Evidence level: Anecdotal case reports

4. Maintenance / Remission Protocol –

• Applicable cancers: All cancer types after achieving NED
• Ivermectin dosage: 0.5–1.0 mg/kg, 3–5 days per week only
• Benzimidazole partner: Fenbendazole 444 mg/day or Mebendazole 500 mg/day
• Key add-ons: Berberine, Vitamin D 10,000–20,000 IU, liposomal Curcumin
• Duration: Indefinite or minimum 1–2 years

Evidence level: Expert opinion / clinical observation

Dr. Makis’s Core Protocol Rules (2025–2026)

• Take ivermectin with a fatty meal for optimal absorption.
• Use only human pharmaceutical-grade 12 mg tablets — never untested veterinary formulations.
• Monitor liver function tests (LFTs) and kidney function every 4–6 weeks throughout treatment.
• Combine with intermittent fasting or a strict ketogenic diet for potential synergistic benefit.
• Topical DMSO combined with ivermectin on accessible tumors may accelerate local response.
• Liver support: Milk thistle (silymarin) 300–600 mg/day is commonly used for hepatoprotection and is generally compatible with this protocol. Discuss with your physician.

Broader Protocol Context

Makis's full protocol includes 7 components for synergy, but ivermectin is a core element. Other key parts (Hybrid orthomolecular protocol 2024):

• Benzimidazoles: Mebendazole 200–1,500 mg/day or Fenbendazole 222–1,000 mg 3–6×/week (depending on cancer grade)
• Vitamin D3: 2,000–50,000 IU/day targeting serum level of 80 ng/mL
• IV Vitamin C: 1.5 g/kg, 2–3×/week for intermediate/high-grade cancers
• Ketogenic diet: Restrict carbohydrates to induce ketosis (glucose-ketone index ≤ 2.0)
• Methylene Blue: 50–100 mg/day in aggressive cases (consult physician for drug interactions)
• Berberine: 500 mg 2–3×/day for metabolic synergy

Precautions:

• Source from reputable pharmacies; avoid if pregnant or with certain contraindications.
• Evidence is anecdotal and preclinical—large trials are lacking.
• Never self treat - need medical supervision to ensure safety first.

Should You Combine Mebendazole with Fenbendazole? 2025 - 2026 Evidence

Yes, under physician guidance—synergy potential high.

• Preclinical: Combination index (CI) values below 1 with analogues; 80–90% xenograft reduction reported (Anticancer Research).
• Clinical Trials: Indirect—mebendazole + temozolomide (EClinicalMedicine 2022); Fenbendazole remains formally untested in RCTs.
• Real-World Cases — Dr. Makis, 100+ Stage 4 Patients:
• 100+ Stage 4 (William Makis): Pancreatic 70-87% shrink (meben AM + fenben PM); breast NED in 6 weeks (combo + ivermectin).
• Triple combination of Ivermectin, Mebendazole and Fenbendazole for Cancer: 18 Case Reports (February 2026)
• Pancreatic cancer: 70–87% shrinkage reported (mebendazole AM + fenbendazole PM schedule)
• Breast cancer: NED in 6 weeks with triple combination (ivermectin + mebendazole + fenbendazole)
• Risks: Liver strain is a known concern with benzimidazole combination therapy. Monitor weekly LFTs during combination use. Also watch for gastrointestinal symptoms including nausea and elevated liver enzymes.

2026 Cohort: Ivermectin + Mebendazole Combination

Hulscher et al., April 2026 — Ivermectin + Mebendazole Combination

A prospective observational study evaluated 197 total patients, of whom 122 had at least 6 months of follow-up. (Hulscher et al., April 2026) 

• 197 total patients

• 122 with ≥6 months follow-up

Reported Outcomes:

• 84.4% Clinical Benefit Rate (CBR)

  • 32.8%: No Evidence of Disease (NED)

  • 15.6%: Tumor regression

  • 36.1%: Stable disease

Safety:

• 25.4% reported mild gastrointestinal side effects

• Most patients continued treatment

Important Context:

• Mixed cancer types (breast, prostate, colorectal, etc.)

• Many patients also used:

  • Conventional treatments

  • Diet/lifestyle interventions

⚠️ Limitations:

• Observational (not randomized)

• Self-reported outcomes

• Potential selection bias

• No control group

Interpretation: Largest real-world dataset to date—but still hypothesis-generating.

Phase 2 RCT: Mebendazole in Stage 4 Colorectal Cancer

A phase 2 randomized controlled trial published in Life Sciences (2022) found that mebendazole added to standard chemotherapy (bevacizumab + FOLFOX4) was well tolerated and significantly improved outcomes:

• Overall response rate: 10% (control) vs. 65% (mebendazole group) at 12 weeks (p = 0.000)
• Progression-free survival: 3 months (control) vs. 9.25 months (mebendazole group) (p = 0.000)

This is currently the strongest controlled trial evidence supporting benzimidazole use in cancer — though it covers mebendazole specifically, not the full ivermectin combination protocol.

Real Patient Outcomes from Dr. Makis's Practice (2025 - 2026 Cases)

All cases below are from Dr. Makis’s 2025–2026 testimonials (X @MakisMD and Substack). These are anonymized anecdotal reports; outcomes may not be representative of all patients following this protocol.

1. 53 year old Canadian woman – Stage 2 Triple Negative Breast Cancer (7.8 cm tumor) → Cancer Free in 7 months (Dec 2024–Jul 2025).
2. 58 year old California CEO – Recurrent Stage 4 Kidney Cancer → Dying tumors in 10 weeks
3. 70 year old Morocco man – Stage 4 Lymphoma → Complete remission in 2.5 months
4. 39 year old Texas woman – Stage 4 Colon with liver mets → CEA from 441 → 21.9 in 4 months
5. 42 year old woman – Stage 4 Kidney Cancer (lungs/liver/shoulder mets) → NED after 1 year
6. 53 year old UK woman – Stage 4 Breast (12 cm tumor) → 68% shrinkage in 2 months.
7. Stage 3 ovarian cancer: 12 mg daily (approx. 0.2 mg/kg for a 60 kg person) with chemotherapy led to complete resolution in 2 months.
8. 83-year-old - Stage 3 follicular lymphoma: 1 mg/kg daily achieved near-total remission in 6 months.
9. 54-year-old - Recurrent prostate cancer: 1.5 mg/kg daily resulted in remission in 4 months.

Reported Success Rate: Dr. Makis reports that among Stage 4 patients who follow the protocol rigorously, a major response or NED rate consistently exceeds 65–70%. This figure reflects outcomes in patients under direct guidance — it does not represent population-level efficacy and should be interpreted cautiously given the absence of a control group.

Read More: Fenbendazole and Ivermectin Cancer Success Stories: 700+ Case Reports Compilation (2026 Edition)

Frequently Asked Drug Interaction & Safety Questions

This section addresses the most frequently asked questions from patients and readers.

Can I combine this protocol with Capecitabine (Xeloda)?

Fenbendazole and mebendazole are both metabolized via CYP2C9/CYP3A4 pathways, which Capecitabine also affects. There is a theoretical drug interaction risk. No formal interaction study exists as of 2026. Patients combining these agents should disclose all medications to their oncologist, increase CBC and LFT monitoring frequency, and proceed only under physician supervision.

What about cirrhosis or elevated liver enzymes?

High-dose ivermectin and benzimidazoles are hepatically metabolized. Patients with pre-existing liver disease (cirrhosis, hepatitis, elevated LFTs) face increased hepatotoxicity risk. If considered at all, this requires specialist supervision, lower starting doses, and more frequent LFT monitoring (every 2–4 weeks minimum).

Is ivermectin appropriate for Multiple Myeloma or Leukemia?

Dr. Makis categorizes these under Protocol 2 (Aggressive/Turbo Cancer) given their hematological nature. Some case reports suggest responses in lymphoma and leukemia. See the dedicated OneDayMD article: Ivermectin and Mebendazole in Lymphoma and Leukemia (February 2026) for specific case reports.

Are there negative interactions with herbal supplements?

Several supplements have been reported by patients without adverse events alongside ivermectin and fenbendazole, including liposomal Vitamin C and D, Vitamin K, Curcumin, Milk Thistle, Vitamin B complex, Turmeric, Magnesium, Krill Oil, and NAC. However, formal interaction data is lacking. Herbs that strongly inhibit or induce CYP450 enzymes (e.g., St. John’s Wort, high-dose grapefruit) may alter drug levels. Always disclose all supplements to your physician.

Does ivermectin help with parasites (non-cancer use)?

Yes — ivermectin is an approved antiparasitic for human use. For parasite treatment, dosing is typically much lower (0.2 mg/kg single dose or short course) than the cancer protocols above. Consult with a physician for appropriate dosing for your region and situation.

Where to Get Ivermectin Safely in 2026

The Wellness Company's Ivermectin and Mebendazole

Ivermectin and mebendazole, both approved for human use, are now available in the US through controlled medical frameworks. The Wellness Company offers a standardized Ivermectin + Mebendazole combination (25 mg ivermectin + 250 mg mebendazole) with the following assurances:

• Prescribed by licensed physicians
• Compounded in US-based pharmacies to pharmaceutical standards
• Standardized dosing (25mg ivermectin + 250mg mebendazole)
• Quality-tested for purity and consistency

This ensures patients are not relying on uncertain sources or inconsistent formulations.

Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.

Important: Do not purchase veterinary ivermectin formulations. Concentration, inactive ingredients, and purity standards differ significantly from human pharmaceutical-grade preparations.

Affiliate Disclosure

OneDayMD has an affiliate relationship with The Wellness Company and may receive compensation from purchases made through our link.

Conclusion

Cancer patients and their families increasingly face situations where conventional oncology has exhausted its options or where aggressive, fast-moving cancers demand a multimodal approach. Repurposed drugs like ivermectin, fenbendazole, and mebendazole represent a growing body of observational and early clinical evidence that warrants serious attention — while demanding honest acknowledgement of the current limitations in the evidence base.

The approach described here is best understood as complementary to, not a replacement for, conventional oncology. Any integration of repurposed therapies should be done in genuine partnership with your healthcare team — weighing the benefit-risk ratio specific to your situation, cancer type, stage, and comorbidities.

Follow us on Substack, X.com and Facebook.

Important Disclaimers:

• This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician you trust. Do not self-medicate without proper bloodwork and medical monitoring.
• Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
• The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
• Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative.
• Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
• Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing.